Announcements Trials
Browse Landscape

Phase

Phase 1 4

Status

Completed 4

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Tumor-Agnostic 4Other solid neoplasm 2Genitourinary 2Gastrointestinal 2Thoracic 1Sarcoma 1Gynecologic 1Dermatologic 1

Conditions

Neoplasms 3Neoplasm Metastasis 1

Interventions

pembrolizumab 94Paclitaxel 85Gemcitabine 83Carboplatin 79Docetaxel 60Cisplatin 58Bevacizumab 58Nivolumab 56Fluorouracil 47Capecitabine 46Magnetic Resonance Spectroscopy 44Radiotherapy 41Irinotecan 40Oxaliplatin 38Erlotinib Hydrochloride 37Pemetrexed 34Leucovorin 34Biopsy 34atezolizumab 33Cetuximab 32Standard of Care 31Trastuzumab 28Cyclophosphamide 28Radiosurgery 27Blood Specimen Collection 27Specimen Handling 26Sorafenib 26Ipilimumab 26Everolimus 26olaparib 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Caffeine × Tumor-Agnostic × Clear all
NCT02740712 2023-06-09

DDI

pharmaand GmbH

Phase 1 Completed
17 enrolled
Tumor-Agnostic

Neoplasms

NCT02688088 2022-10-18

A Study of Abemaciclib in Participants With Cancer That is Advanced or Has Spread to Another Part(s) of the Body

Eli Lilly and Company

Phase 1 Completed
48 enrolled 30 charts
Tumor-Agnostic

Neoplasm Metastasis

NCT01596647 2020-12-21

Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid Tumors

Novartis

Phase 1 Completed
39 enrolled
Tumor-Agnostic

Neoplasms

NCT01517399 2019-02-12

Drug-drug Interaction Study of Tivantinib (ARQ 197) With Omeprazole, S-warfarin, Caffeine, Midazolam, and Digoxin in Cancer Subjects

Daiichi Sankyo

Phase 1 Completed
28 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡